Roos A. Wagensveld

Roos A. Wagensveld

Auto-generated profile, based on publicly available information

Roos A. Wagensveld


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2025 in bioRxiv
Verified
Preprint
Open access
PKPaulien Kaptein
Paulien Kaptein
NSNadine Slingerland
Nadine Slingerland
ALAnne M. van der Leun
Anne M. van der Leun
EREline Runderkamp
Eline Runderkamp
RWRoos A. Wagensveld
Roos A. Wagensveld
DTDaniela S. Thommen
Daniela S. Thommen
T cells are key effectors of antitumor responses elicited by PD-1 blockade. However, it remains elusive by which mechanism(s) PD-1 blockade initiates T cell-driven antitumor immunity in cancer tissues. Here, we dissect early T cell reactivation upon anti-PD-1 in patient-derived tumor fragments. Using bispecific antibodies to target anti-PD-1 to individual T cell subsets, we demonstrate that intratumoral CD8 + and CD4 + T cells can independently drive immune remodeling of the tumor microenvironment. The CD8 + and CD4 + T cells that respond to anti- PD-1 exhibit a shared dysfunctional gene program, characterized by tumor-reactivity, terminal exhaustion, effector capacity, and reduced translational activity. Notably, rather than acting through transcriptional rewiring, anti-PD-1 reinvigorates dysfunctional T cells by overcoming this translational barrier, resulting in restored effector function. Altogether, these results reveal dysfunctional T cells as initiators of early tissue responses to PD-1 blockade and identify a novel mode of their therapeutic reinvigoration through restoration of translational control. One Sentence Summary: Translational reactivation of tumor-residing dysfunctional T cells drives early intratumoral immune activity upon PD-1 blockade.